Turn Therapeutics

Turn Therapeutics

Turn Therapeutics operates as a clinical-stage biotech and specialty pharmaceutical company formed to address drug-resistant infections and chronic inflammatory conditions. Founder Bradley Burnam established the firm around a proprietary formulation combining multiple broad-spectrum antimicrobial and anti-inflammatory agents into a single hydrophobic base, aiming to solve pathogen resistance and biofilm penetration without relying on traditional single-mechanism antibiotics. The core technology originated from Burnam's earlier research into topical solutions for persistent skin and soft-tissue infections. The firm's primary asset is the FDA-cleared Hexagen platform, which has received 510(k) clearance for prescription use in managing partial and full-thickness wounds, including diabetic ulcers and venous stasis ulcers. KerraCure, its flagship product, is a wound gel distributed through a licensing partnership with a major established wound-care supplier, allowing Turn Therapeutics to penetrate the chronic-wound market without a capital-intensive commercial build. The company targets the advanced wound dressings segment, an area where hospital systems seek alternatives to silver-based topicals and standard hydrogel dressings. Additional pipeline programs include a topical compound for eczema and atopic dermatitis, and a formulation intended for post-surgical infection prophylaxis. Turn Therapeutics maintains a lean operational footprint. While the exact headcount and total deployment remain undisclosed, the company has historically conducted clinical work and regulatory submissions with a small internal team supplemented by external CROs and academic collaborators. The firm has previously disclosed research partnerships with U.S. academic dermatology departments to validate its formulations against methicillin-resistant Staphylococcus aureus and Candida auris. The licensing structure for KerraCure provides royalty-based recurring revenue without direct hospital sales infrastructure. In recent years, public communications have focused on expanding the patent estate around Hexagen and pursuing additional FDA indications. What structurally differentiates Turn Therapeutics is its dual licensing-and-development model. Instead of raising successive large venture rounds to fund a costly internal sales organization, the firm monetizes its approved product through an exclusive license while retaining the rights to develop new chemical entities on the same platform. This structure preserves equity value around the pipeline without the dilution and fixed costs of a fully integrated pharmaceutical sales force. The firm's long-term posture appears aimed at building a portfolio of licensable topical therapeutics, with any future direct commercialization likely reserved for over-the-counter products with retail-channel economics.